Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity

What Was Tested

The paper reports a study of Tirzepatide and Semaglutide in the context of fat loss, obesity & body recomposition, published as an observational study.

To compare on-treatment weight loss and rates of gastrointestinal adverse events (AEs) among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes (T2D) in a clinical setting.

Why It Was Studied

Tirzepatide or semaglutide in formulations labeled for T2D, on or off label.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems.

On-treatment weight outcomes through November 3, 2023, were assessed.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

The analysis was completed on April 3, 2024.

What Was Measured

Topics PubMed links to this paper include Tirzepatide, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists, Anti-Obesity Agents, Weight Loss, Overweight and Obesity.

What This Means in Plain Language

The paper is a randomized study of Tirzepatide and Semaglutide in people with fat loss, obesity & body recomposition.

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (JAMA internal medicine), a journal based in United States.

More context: the Tirzepatide compound page and the Semaglutide compound page, Fat loss, obesity & body recomposition research.